Free Access
| Issue |
Med Sci (Paris)
Volume 35, Mars 2019
JRC 2018 – Innovation et parcours de soins
|
|
|---|---|---|
| Page(s) | 18 - 21 | |
| Section | Journée de Recherche Clinique 2018 | |
| DOI | https://doi.org/10.1051/medsci/2019021 | |
| Published online | 03 April 2019 | |
- Bijvoet AG, Kroos MA, Pieper FR, et al. Expression of cDNA-encoded human acid alpha-glucosidase in milk of transgenic mice. Biochim Biophys Acta 1996 ; 1308 : 93–96. [CrossRef] [PubMed] [Google Scholar]
- Van den Hout JM, Reuser AJ, de Klerk JB, et al. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001 ; 24 : 266–274. [CrossRef] [PubMed] [Google Scholar]
- Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001 ; 3 : 132–138. [PubMed] [Google Scholar]
- Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol 2004 ; 55 : 495–502. [CrossRef] [PubMed] [Google Scholar]
- Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007 ; 68 : 99–109. [Google Scholar]
- Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006 ; 148 : 671–676. [CrossRef] [PubMed] [Google Scholar]
- van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010 ; 362 : 1396–1406. [Google Scholar]
- Orlikowski D, Laforêt P, Pellegrini N, et al. Effects of one year enzyme replacement therapy in severe form of late onset pompe disease. Severe late onset treatment study (French slots). Congrès international de myologie. Myology 2008. Marseille : Abstracts book, mai 2008, p. 355. [Google Scholar]
- Haute autorité de santé. Avis du 22 mars 2017 de la Commission de la transparence - Myozyme (sur www.has-sante.fr). [Google Scholar]
- Schoser B, Laforêt P, Kruijshaar ME, et al. 208th ENMC international workshop: formation of a European network to develop a European data sharing model and treatment guidelines for Pompe disease. Neuromuscul Disord 2015 ; 25 : 674–678. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.